• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Surgical

The biggest stories from the American Diabetes Association (ADA) 2023 Scientific Sessions

June 30, 2023 By Sean Whooley

American Diabetes Association ADA 2023 Medtronic MiniMed 780G Insulet Omnipod 5 Senseonics Eversense E3 GLP-1s

As it does every year, this past week, the American Diabetes Association convened its Scientific Sessions to bring together leaders in the diabetes space. At last year’s event, next-generation technologies from the big hitters took the spotlight. The 83rd iteration this past week produced a range of new studies, product updates and positive news for […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Pediatrics, Pharmaceuticals, Surgical, Technology, Wall Street Beat Tagged With: abbott, ADA 2023, American Diabetes Association, Bigfoot Biomedical, Dexcom, Eli Lilly & Co., Fractyl Health, Insulet, Medtronic, Novo Nordisk, Senseonics, Sernova Inc, Vida Health, Virta Health

Studies back Fractyl Health diabetes reversal procedure, gene therapy

June 26, 2023 By Sean Whooley

This is the logo of Fractyl Health.

Fractyl Health announced multiple studies supporting its programs for the reversal and treatment of diabetes. Lexington, Massachusetts-based Fractyl reported data from its Revitalize 1 pivotal study and its Rejuva program. Revitalize 1 evaluates the company’s Revita endoscopic ablation procedure to reverse diabetes. Rejuva evaluates a targeted pancreatic gene therapy. The company presented its results at […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Surgical Tagged With: ADA 2023, American Diabetes Association, Fractyl Health

Fractyl Health initiates global registry for diabetes reversal treatment

April 25, 2023 By Sean Whooley

This is the logo of Fractyl Health.

Fractyl Health announced that it initiated its Revita Global Registry Program in Germany to study its diabetes reversal treatment. On April 20, the Ethics Committee of the University of Freiburg (Germany) granted clearance for the initiation of a registry study. The study covers the Revita system in German hospitals. Patients in the registry have inadequately […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Surgical Tagged With: Fractyl Health

Endogenex taps former Medtronic executive as CEO

March 23, 2023 By Sean Whooley

Portrait photo of Endogenex CEO Stacey Pugh

Endogenex, developer of a procedure for treating type 2 diabetes, announced today that it appointed Stacey Pugh as its new CEO. Pugh’s responsibilities at Minneapolis-based Endogenex include expanding the company’s clinical initiatives evaluating its ReCET procedure. ReCET — a novel, endoscopic, outpatient procedure — targets the underlying cellular abnormalities in the duodenum. These abnormalities contribute […]

Filed Under: Business/Financial News, Diabetes, Featured, Personnel, Surgical Tagged With: Endogenex, Personnel Moves

Fractyl Health launches diabetes reversal treatment in Germany

February 7, 2023 By Sean Whooley

This is the logo of Fractyl Health.

Fractyl Health announced today that it commercially launched its Revita DMR system for diabetes reversal in Germany. Revita, an endoscopic procedural therapy, remodels the duodenal lining through hydrothermal ablation. This tackles a root cause of type 2 diabetes. Revita holds CE mark approval in Europe and established reimbursement in Germany recently. Lexington, Massachusetts-based Fractyl performed […]

Filed Under: Business/Financial News, Diabetes, Surgical Tagged With: Fractyl Health

Fractyl Health forms task force to understand root causes of type 2 diabetes

November 2, 2022 By Sean Whooley

This is the logo of Fractyl Health.

Fractyl Health announced today that it created the Erase T2D task force to research type 2 diabetes in the hopes of “erasing” the condition. The academic-industry scientific partnership aims to advance research on the role of the gut in metabolic disease. This, in turn, could catalyze future discoveries on understanding and erasing type 2 diabetes. […]

Filed Under: Business/Financial News, Diabetes, Featured, Surgical Tagged With: Fractyl Health

Data supports GI Dynamics’ type 2 diabetes treatment

July 14, 2022 By Sean Whooley

GI Dynamics Logo

GI Dynamics announced today that results from a registry for its EndoBarrier for type 2 diabetes were positive. Data from use of the EndoBarrier within the National Health Service (NHS) in the UK were presented by Dr. Robert Ryder of City Hospital (Birmingham, UK) at the American Diabetes Association Scientific Sessions last month, according to […]

Filed Under: Clinical Trials, Diabetes, Surgical Tagged With: GI Dynamics

Fractyl Health touts preliminary data from diabetes reversal study

January 20, 2022 By Sean Whooley

This is the logo of Fractyl Health.

Fractyl Health this week announced encouraging interim feasibility data from its diabetes reversal technology study. Lexington, Massachusetts–based Fractyl’s Revita-T2Di long-term open-label cohort assessed eight patients followed through at least four weeks having been treated. The company’s Revita system resurfaces the upper intestine lining (duodenal mucosa) to treat metabolic disease in patients with insulin-treated type 2 […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Featured, Surgical Tagged With: Fractyl Health, fractyllaboratories

Innocoll Biotherapeutics initiates Phase 3 trials for collagen drug-device

April 14, 2021 By Sean Whooley

Innocoll

Innocoll Biotherapeutics announced today that it initiated two Phase 3 trials to support a label expansion for its collagen drug-device implant. Athlone, Ireland-based Innocoll’s trials are seeking label expansion for the FDA-approved Xaracoll (bupivacaine hydrochloride) implant, according to a news release. INN-CB-024, a Phase 3, randomized, double-blind, placebo-controlled study is evaluating the efficacy and safety […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Surgical Tagged With: innocoll

How Bionaut Labs aims to tackle brain tumors with microrobots

March 15, 2021 By Brian Buntz

Bionaut Labs

The roboticist Michael Shpigelmacher was one of the founders of PrimeSense, a robotic 3-D vision technology company Apple acquired in 2013. PrimeSense created technology empowering the Microsoft Xbox Kinect and the iPhone’s Face ID feature, allowing users to use facial recognition to unlock their phones.  Now Shpigelmacher has set his sights on drug-delivery with Bionaut […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Funding Roundup, Neurological, Oncology, Surgical, Technology Tagged With: 510(k), Bionaut Labs, glioma, Michael Shpigelmacher, Microsoft Kinect, neurology, oncology, PrimeSense

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 7
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS